Diabetic Nephropathy

Detailed Overview

It is the leading cause of chronic kidney disease (CKD) and ESRD worldwide. Chronic hyperglycemia drives glomerular hyperfiltration, mesangial expansion, and podocyte injury. The disease initially presents silently with microalbuminuria, progressing to macroalbuminuria, and then steadily declining renal function over years. Strict glycemic and blood pressure control are the cornerstones of preventing progression.

Epidemiology & Demographics

Affects 20-40% of patients with diabetes. It is the single leading cause of ESRD in the US, accounting for ~45% of cases. Higher prevalence in African American, Hispanic, and Native American populations.

Etiological Mechanism

Caused by sustained hyperglycemia and uncontrolled hypertension in the setting of long-standing diabetes.

Primary Causes

Type 1 and Type 2 Diabetes Mellitus.

• Poor glycemic control: Chronically elevated HbA1c > 7%.
• Hypertension: Uncontrolled systemic BP transmits pressure to glomeruli.
• Genetics and race: Family history of DKD; African American or Native American descent.

Hyperglycemia leads to accumulation of advanced glycation end products (AGEs), activating protein kinase C and increasing TGF-beta, which promotes fibrosis. Afferent arteriolar vasodilation (from IGF-1 and NO) and efferent arteriolar vasoconstriction (from Angiotensin II) cause glomerular capillary hypertension and hyperfiltration. Over time, this mechanical stress and metabolic injury lead to mesangial cell proliferation, thickening of the glomerular basement membrane, and podocyte loss. The classic histologic lesion is nodular glomerulosclerosis (Kimmelstiel-Wilson nodules). This structural damage increases glomerular permeability, resulting in albuminuria, and eventually destroys nephrons, decreasing GFR.

Characteristic Clinical Presentation

• Asymptomatic early on: Usually no symptoms until advanced stages of CKD.
• Peripheral edema: Swelling in the legs and ankles due to hypoalbuminemia and fluid retention.
• Fatigue and pallor: Due to anemia of chronic kidney disease (decreased EPO production).
• Uremic symptoms: Nausea, vomiting, pruritus, and confusion in stage 5 CKD (ESRD).

Physical Examination Signs

• Elevated blood pressure.
• Pitting pedal edema.
• Frothy urine (due to heavy proteinuria).

• End-Stage Renal Disease (ESRD): Absolute requirement for renal replacement therapy.
• Cardiovascular Disease: Exponentially increased risk of MI, stroke, and heart failure.
• Hyperkalemia: Due to decreased renal potassium excretion and type 4 renal tubular acidosis.

Diagnostic Criteria & Guidelines

Persistent albuminuria defined as UACR >= 30 mg/g on two of three samples collected over 3-6 months, or persistent reduction in eGFR < 60 mL/min/1.73m2, in a patient with diabetes, without signs of other primary kidney disease.

Differential Diagnosis

• Hypertensive nephrosclerosis
• Primary glomerulonephritis (e.g., IgA nephropathy)
• Renal artery stenosis

Laboratory Tests & Biomarkers

• Urine Albumin-to-Creatinine Ratio (UACR): Elevated > 30 mg/g.
• Serum Creatinine/eGFR: Elevated creatinine, decreased eGFR (<60 mL/min/1.73m2 in later stages).
• Hemoglobin A1c: Usually elevated (> 7.0%), reflecting poor glycemic control.

Imaging Modalities & Findings

• Renal Ultrasound: Kidneys are typically normal or enlarged in size (unlike other CKD which shows small, shrunken kidneys) until very late stages.

• Stage 1 (Hyperfiltration)
  Elevated GFR (>120 mL/min) with normal urine albumin.
• Stage 2/3 (Microalbuminuria)
  Urine albumin-to-creatinine ratio (UACR) 30-300 mg/g; GFR starts to fall to normal.
• Stage 4 (Macroalbuminuria)
  UACR > 300 mg/g; steady, irreversible decline in GFR.
• Stage 5 (ESRD)
  GFR < 15 mL/min/1.73m2, requiring dialysis or transplant.

Second-Line & Adjunctive Therapy

Non-steroidal mineralocorticoid receptor antagonists (e.g., Finerenone 10-20 mg PO daily) to reduce proteinuria and CV events if eGFR >= 25 mL/min/1.73m2. GLP-1 receptor agonists (e.g., Semaglutide) if SGLT2i are not tolerated or insufficient for glycemic control.

Surgical & Procedural Management

Kidney transplantation for ESRD. Dialysis access creation (AV fistula or peritoneal dialysis catheter) when GFR < 15-20 mL/min.

Recommended Lifestyle Changes

• Dietary protein restriction (0.8 g/kg/day) for non-dialysis patients.
• Low sodium diet (< 2 g/day) to enhance BP control and reduce edema.
• Smoking cessation to slow CKD progression.

Patient Counseling & Advice

Explain that ACEi/ARBs protect the kidney even if blood pressure is normal. Emphasize that strict blood sugar control early in the disease is the best way to prevent needing dialysis.

Follow-Up & Monitoring Schedule

Annual screening of UACR and eGFR in all type 2 diabetics at diagnosis, and in type 1 diabetics 5 years after diagnosis. If UACR is elevated, monitor every 3-6 months along with serum potassium.

Preventive Strategies

Strict primary glycemic control (HbA1c < 7%) and blood pressure control. Avoiding nephrotoxic agents like NSAIDs and IV contrast when possible.

If untreated, progression from microalbuminuria to macroalbuminuria takes ~5-10 years, and from macroalbuminuria to ESRD takes another 5-10 years. Cardiovascular mortality is the most common cause of death.